FindMyKOL
Clinical trialNCT01728207TerminatedPhase 1Interventional

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

SponsorGilead SciencesEnrollment30Chronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaNon-hodgkin's LymphomaSmall Lymphocytic Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

IMMU-114 will be studied at different dose schedules and dose levels in order to assess the highest dose safely tolerated. IMMU-114 will be administered subcutaneously (under the skin). IMMU-114 will be given 1-2 times weekly for 3 weeks followed by one week of rest. This is considered one cycle. Treatment cycles will be repeated until toxicity or worsening of disease.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Helen F Graham Cancer Center

    Newark, Delaware, United States

  • Nancy N. and J.C. Lewis Cancer and Research Pavilion

    Savannah, Georgia, United States

  • Indiana University Health Goshen Hospital

    Goshen, Indiana, United States

  • the Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

  • Huntsman Cancer Institute, Univ. Utah

    Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IMMU-114
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2013
Primary completion
31 Mar 2017
Completion
31 Mar 2017
Last update posted
19 Aug 2021
Registered enrollment
30
Registry id
NCT01728207
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.